ATXS

5.11

4.66% -0.25

Handel nachbörslich: 5.11

Astria Therapeutics Inc (ATXS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.36

Offen:

$5.3

24-Stunden-Volumen:

223.69K

Relative Volume:

0.67

Marktkapitalisierung:

$279.91M

Einnahmen:

Nettoeinkommen (Verlust:

$-72.89M

KGV:

-2.1116

EPS:

-2.42

Netto-Cashflow:

$-68.47M

1W Leistung:

+3.02%

1M Leistung:

+9.77%

6M Leistung:

-55.60%

1J Leistung:

-46.49%

1-Tages-Spanne:

$5.10

$5.36

1-Wochen-Bereich:

$5.01

$5.47

52-Wochen-Spanne:

$3.555

$12.92

Astria Therapeutics Inc Stock (ATXS) Company Profile

Firmenname

Astria Therapeutics Inc

Sektor

Healthcare (1150)

Branche

Biotechnology (676)

Telefon

617-349-1971

Adresse

22 BOSTON WHARF ROAD, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-11

Neueste SEC-Einreichungen

ATXS's Discussions on Twitter

Vergleichen Sie ATXS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATXS Astria Therapeutics Inc	5.11	279.91M	0	-72.89M	-68.47M	-2.42
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-01-31	Eingeleitet	JMP Securities	Mkt Outperform
2024-07-29	Eingeleitet	TD Cowen	Buy
2023-03-28	Eingeleitet	Evercore ISI	Outperform

Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten

May 05, 2025

Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView

May 05, 2025

Invesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 05, 2025

May 02, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus

May 02, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

May 02, 2025

Wall Street analysts’ outlook for Astria Therapeutics Inc (ATXS) - Sete News

May 02, 2025

Financial Metrics Check: Astria Therapeutics Inc (ATXS)’s Ratios for Trailing Twelve Months - DWinneX

May 02, 2025

Astria Therapeutics reports progress in HAE drug trial By Investing.com - Investing.com India

May 01, 2025

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology - Business Wire

May 01, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Holdings Increased by Legal & General Group Plc - Defense World

May 01, 2025

Astria Therapeutics (ATXS) to Release Quarterly Earnings on Thursday - Defense World

May 01, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Position Increased by JPMorgan Chase & Co. - Defense World

May 01, 2025

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference | ATXS Stock News - GuruFocus

May 01, 2025

Cantor Fitzgerald Upgrades Astria Therapeutics (NASDAQ:ATXS) to “Strong-Buy” - Defense World

May 01, 2025

Apr 30, 2025

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference - Business Wire

Apr 30, 2025

Apr 29, 2025

Astria Therapeutics (ATXS) Receives Overweight Rating with Promi - GuruFocus

Apr 29, 2025

Cantor Fitzgerald Initiates Coverage of Astria Therapeutics (ATXS) with Overweight Recommendation - Nasdaq

Apr 29, 2025

Apr 26, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Consensus Price Target from Analysts - Defense World

Apr 26, 2025

Apr 25, 2025

Ratios Revealed: Decoding Astria Therapeutics Inc (ATXS)’s Financial Health - DWinneX

Apr 25, 2025

Apr 24, 2025